BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

7043 related articles for article (PubMed ID: 2669619)

  • 1. Viral oncolysates in cancer treatment: immunological mechanisms of action (review).
    Ioannides CG; Platsoucas CD; O'Brian CA; Patenia R; Bowen JM; Wharton JT; Freedman RS
    Anticancer Res; 1989; 9(3):535-44. PubMed ID: 2669619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological effects of tumor vaccines: II. T cell responses directed against cellular antigens in the viral oncolysates.
    Ioannides CG; Platsoucas CD; Freedman RS
    In Vivo; 1990; 4(1):17-24. PubMed ID: 2103838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell functions in ovarian cancer patients treated with viral oncolysates: I. Increased helper activity to immunoglobulins production.
    Ioannides CG; Platsoucas CD; Patenia R; Kim YP; Bowen JM; Morris M; Edwards C; Wharton JT; Freedman RS
    Anticancer Res; 1990; 10(3):645-53. PubMed ID: 2142392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
    Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
    Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active immunization against cancer cells: impediments and advances.
    Velders MP; Schreiber H; Kast WM
    Semin Oncol; 1998 Dec; 25(6):697-706. PubMed ID: 9865683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant viral vectors: cancer vaccines.
    Harrop R; John J; Carroll MW
    Adv Drug Deliv Rev; 2006 Oct; 58(8):931-47. PubMed ID: 17030074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
    Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
    Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring cellular immune responses to cancer immunotherapy.
    Morse MA; Clay TM; Hobeika AC; Mosca PJ; Lyerly HK
    Curr Opin Mol Ther; 2001 Feb; 3(1):45-52. PubMed ID: 11249731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunization against the human immunodeficiency virus in Zaire].
    Zagury D; Salaün JJ; Bernard J; Dechazal L; Goussard B; Lurhuma Z
    Med Trop (Mars); 1988; 48(4):417-23. PubMed ID: 3221792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.
    Sinkovics JG; Horvath JC
    Arch Immunol Ther Exp (Warsz); 2008 Dec; 56 Suppl 1():3s-59s. PubMed ID: 19104757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
    Xia D; Moyana T; Xiang J
    Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor vaccination: where we stand.
    Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
    Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
    Peggs KS; Quezada SA; Allison JP
    Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The anti-idiotype vaccines for immunotherapy.
    Bhattacharya-Chatterjee M; Chatterjee SK; Foon KA
    Curr Opin Mol Ther; 2001 Feb; 3(1):63-9. PubMed ID: 11249733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer immunogene therapy.
    Yoshizawa H; Kagamu H; Gejyo F
    Arch Immunol Ther Exp (Warsz); 2001; 49(5):337-43. PubMed ID: 11798131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 353.